Latest press releases
Filter by topic
- All
- Corporate
- Advanced Wound Care
- Continence Care
- Infusion Care
- Ostomy Care
- Our People
- Communities
- Financial Performance
Filter by year
02-Oct-25
Convatec announces pricing of $500 Million 5.300% Senior Notes due 2035
01-Oct-25
Convatec announces plans to invest more than $1 billion in R&D facilities – major expansions in the US and UK
29-Sep-25
Convatec announces offering of Senior Notes
22-Sep-25
Convatec secures regulatory approval for ConvaMatrix™ in UK and Europe, supporting more patients with pioneering skin substitute technology
02-Sep-25
Convatec strengthens Leadership Team to support growth
20-Aug-25
Convatec commences share buyback programme
04-Aug-25
Update regarding Chief Executive Officer
29-Jul-25
Interim results for the six months ended 30 June 2025
24-Jul-25
Convatec secures US and European regulatory clearance for Aquacel™ ConvaFiber™ wound care innovation
15-Jul-25
Convatec responds to CMS draft payment proposal for skin substitutes in the United States
01-Jul-25
Comment on CMS proposed rule change issued 30 June 2025
26-Jun-25
Convatec welcomes regulatory approval of subcutaneous apomorphine infusion for advanced Parkinson’s disease in the US
22-May-25
AGM trading update for the four months ended 30 April 2025
20-May-25
Advancing subcutaneous infusion therapy for patients through innovation and partnerships
25-Apr-25
Convatec receives regulatory approval for ConvaNiox™
11-Apr-25
Convatec welcomes postponement of Local Coverage Determinations (LCDs) on skin substitutes until January 2026
Fact sheet
Learn moreLearn more about the medical solutions we offer
Learn more